HC Wainwright Has Bullish Forecast for ALNY Q3 Earnings

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Stock analysts at HC Wainwright increased their Q3 2025 earnings per share estimates for shares of Alnylam Pharmaceuticals in a report released on Wednesday, April 2nd. HC Wainwright analyst P. Trucchio now anticipates that the biopharmaceutical company will earn ($0.45) per share for the quarter, up from their previous forecast of ($0.46). HC Wainwright has a “Buy” rating and a $500.00 price objective on the stock. The consensus estimate for Alnylam Pharmaceuticals’ current full-year earnings is ($1.70) per share. HC Wainwright also issued estimates for Alnylam Pharmaceuticals’ Q4 2025 earnings at $1.38 EPS, FY2025 earnings at ($1.32) EPS and FY2026 earnings at $12.37 EPS.

Several other equities analysts also recently commented on the stock. Bank of America increased their target price on shares of Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the stock a “buy” rating in a research report on Friday, March 21st. Morgan Stanley increased their price objective on Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the company an “equal weight” rating in a report on Friday, February 14th. JPMorgan Chase & Co. raised Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $280.00 to $328.00 in a research note on Monday, March 24th. Chardan Capital reaffirmed a “buy” rating and set a $300.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. Finally, Needham & Company LLC reiterated a “buy” rating and set a $320.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, March 21st. One research analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-one have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $316.25.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $235.74 on Monday. The firm has a market cap of $30.67 billion, a price-to-earnings ratio of -108.64 and a beta of 0.30. The company’s fifty day moving average is $259.03 and its 200-day moving average is $260.14. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals has a 12 month low of $141.98 and a 12 month high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.03).

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Versant Capital Management Inc raised its stake in Alnylam Pharmaceuticals by 76.8% during the first quarter. Versant Capital Management Inc now owns 336 shares of the biopharmaceutical company’s stock worth $91,000 after acquiring an additional 146 shares in the last quarter. California State Teachers Retirement System grew its holdings in shares of Alnylam Pharmaceuticals by 2.6% in the 4th quarter. California State Teachers Retirement System now owns 196,362 shares of the biopharmaceutical company’s stock worth $46,206,000 after purchasing an additional 5,037 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its position in shares of Alnylam Pharmaceuticals by 94.7% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 12,566 shares of the biopharmaceutical company’s stock worth $2,957,000 after purchasing an additional 6,112 shares in the last quarter. Lansforsakringar Fondforvaltning AB publ bought a new position in Alnylam Pharmaceuticals during the 4th quarter valued at about $10,011,000. Finally, Bannerman Wealth Management Group LLC acquired a new position in Alnylam Pharmaceuticals in the fourth quarter valued at about $327,000. 92.97% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Alnylam Pharmaceuticals

In related news, CFO Jeffrey V. Poulton sold 967 shares of the stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $246,749.39. Following the completion of the transaction, the chief financial officer now owns 32,786 shares of the company’s stock, valued at $8,366,003.62. This represents a 2.86 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $255.21, for a total value of $169,204.23. Following the sale, the executive vice president now directly owns 14,321 shares in the company, valued at $3,654,862.41. The trade was a 4.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 71,234 shares of company stock valued at $19,958,097. 1.50% of the stock is owned by corporate insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.